Zahnarzt Perren
  • Willkommen
  • Notfalldienst
  • Praxis
  • Angebot
  • Team
  • Über uns
  • Contact
  • Links
  • Menü Menü
DE | EN | ES | IT | FR | PL | EL | PT

Persistent phototransformation products of vardenafil (Levitra®) and sildenafil (Viagra®)

Levitra > liquid levitra


  • 6.2 Postmarketing Experience
  • Programar Citas para el Tratamiento de la DE en New York Urology Specialists
  • Lo Que Necesita Saber:
  • Overdose/Missed Dose
  • Therapeutic indication
  • Related services & treatments

In cases of overdose, standard supportive measures should be taken as required.

Storage Condition Temperature Range Light Exposure Shelf Life Notes
Cool, dry place 15-25°C Keep away from direct light 2 years Keep out of reach of children
Avoid freezing - Yes Protect from moisture
Bottle tightly closed - - Prevent contamination
Store away from heat sources - - Maintain stability

11 DESCRIPTION Vardenafil orally disintegrating tablet, USP is an oral therapy for the treatment of erectile dysfunction.

Ingredient Concentration Purpose Notes
Vardenafil Hydrochloride 20 mg/mL Active component for erectile dysfunction relief Prescribed dose varies
Glycerin 10% Solvent and base Enhances absorption
Purified Water Q.S. to 100% Diluent Ensures stability
Flavoring Agents - Improves taste Commonly mint or berry

This monohydrochloride salt of vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific PDE5.Vardenafil HCl is designated chemically as piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-, monohydrochloride and has the following structural formula:Vardenafil HCl trihydrate is a nearly colorless, solid substance with a molecular weight of 579.1 g/mol and a solubility of 0.11 mg/mL in water.Vardenafil orally disintegrating tablet,USP is formulated as white round orally disintegrating tablets with debossing.

6.2 Postmarketing Experience

Environ. Pollut.

How effective are vardenafil and tadalafil for erectile dysfunction?

Each tablet contains 11.85 mg vardenafil , which corresponds to 10 mg vardenafil hydrochloride, and the following inactive ingredients: microcrystalline cellulose, lactose anhydrous, crospovidone, colloidal silicon dioxide, sodium chloride, natural flavor, maize maltodextrin, Modified corn starch, pulegone, aspartame and sodium stearyl fumarate.

  • Patients should inform their doctor of all medications.
  • Interactions with nitrate drugs are dangerous.
  • Always consult before combining with other medicines.

Vardenafil orally disintegrating tablet, USP is an oral therapy for the treatment levitra 20 brand of erectile dysfunction. Vardenafil HCl is designated chemically as piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-, monohydrochloride and has the following structural formula: Vardenafil HCl trihydrate is a nearly colorless, solid substance with a molecular weight of 579.1 g/mol and a solubility of 0.11 mg/mL in water.

Product Dosage Quantity + Bonus Price
Levitra Original20mg22 + 2 Pills138.55€ 131.95€
Levitra Original20mg76 + 4 Pills344.39€ 327.99€
Levitra Original20mg64 + 4 Pills298.45€ 284.24€
Levitra Generic20mg30 + 4 Pills70.59€ 67.23€
Levitra Generic60mg120 + 8 Pills372.33€ 354.60€
Levitra Generic60mg180 + 10 Pills501.43€ 477.55€
Levitra Original20mg34 + 2 Pills188.51€ 179.53€
Levitra Generic20mg60 + 6 Pills131.11€ 124.87€
Levitra Soft Tabs20mg360 + 20 Pills682.21€ 649.72€
Levitra Soft Tabs20mg270 + 10 Pills521.78€ 496.93€
Levitra Generic60mg270 + 10 Pills714.53€ 680.50€
Levitra Original20mg48 + 4 Pills235.14€ 223.94€
Levitra Generic40mg360 + 10 Pills704.99€ 671.42€
Levitra Generic40mg90 + 6 Pills234.73€ 223.55€
Levitra Soft Tabs20mg30 + 2 Pills99.17€ 94.45€

Vardenafil orally disintegrating tablet,USP is formulated as white round orally disintegrating tablets with debossing. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of ActionPenile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. The most abundant PDE in the human corpus cavernosum is the cGMP-specific PDE5; therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

Programar Citas para el Tratamiento de la DE en New York Urology Specialists

Because sexual stimulation is required to initiate the local release of nitric oxide, the inhibition of PDE5 has no effect in the absence of sexual stimulation.In vitro studies have shown that vardenafil is a selective inhibitor of PDE5.

Formulation Average Cost per Dose Convenience Onset Speed Storage Notes
Liquid Levitra $5 - $10 High Faster Refrigeration optional Suitable for precise dosing
Tablet Levitra $4 - $8 per tablet Moderate Slightly slower Standard storage Widely available, stable
Generic versions $3 - $7 per dose Varies Similar Varies Cost-effective alternative

The inhibitory effect of vardenafil is more selective on PDE5 than for other known phosphodiesterases (>15-fold relative to PDE6, >130-fold relative to PDE1, >300-fold relative to PDE11, and >1,000-fold relative to PDE2, 3, 4, 7, 8, 9, and 10).12.2 PharmacodynamicsThe pharmacodynamic studies described below were conducted using vardenafil film-coated tablets.Effects on Blood PressureIn a clinical pharmacology study of patients with erectile dysfunction, single doses of vardenafil 20 mg film-coated tablets caused a mean maximum decrease in supine blood pressure of 7 mmHg systolic and 8 mmHg diastolic (compared to placebo), accompanied by a mean maximum increase of heart rate of 4 beats per minute. Vardenafil may add to the blood pressure lowering effects of antihypertensive agents [see Drug Interactions (7)].Effects on Blood Pressure and Heart Rate when Vardenafil is Combined with NitratesA study was conducted in which the blood pressure and heart rate response to 0.4 mg nitroglycerin (NTG) sublingually was evaluated in 18 healthy subjects following pretreatment with vardenafil 20 mg film-coated tablets at various times before NTG administration.

Lo Que Necesita Saber:

In cases of overdose, standard supportive measures should be taken as required. 11 DESCRIPTION Vardenafil orally disintegrating tablet, USP is an oral therapy for the treatment of erectile dysfunction. This monohydrochloride salt of vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific PDE5.Vardenafil HCl is designated chemically as piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-, monohydrochloride and has the following structural formula:Vardenafil HCl trihydrate is a nearly colorless, solid substance with a molecular weight of 579.1 g/mol and a solubility of 0.11 mg/mL in water.Vardenafil orally disintegrating tablet,USP is formulated as white round orally disintegrating tablets with debossing. Each tablet contains 11.85 mg vardenafil , which corresponds to 10 mg vardenafil hydrochloride, and the following inactive ingredients: microcrystalline cellulose, lactose anhydrous, crospovidone, colloidal silicon dioxide, sodium chloride, natural flavor, maize maltodextrin, Modified corn starch, pulegone, aspartame and sodium stearyl fumarate. Vardenafil orally disintegrating tablet, USP is an oral therapy for the treatment levitra 20 brand of erectile dysfunction.

Photolytic degradation of norfloxacin, enrofloxacin and ciprofloxacin in various aqueous media

Vardenafil HCl is designated chemically as piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-, monohydrochloride and has the following structural formula: Vardenafil HCl trihydrate is a nearly colorless, solid substance with a molecular weight of 579.1 g/mol and a solubility of 0.11 mg/mL in water. Vardenafil orally disintegrating tablet,USP is formulated as white round orally disintegrating tablets with debossing. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of ActionPenile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. The most abundant PDE in the human corpus cavernosum is the cGMP-specific PDE5; therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP. Because sexual stimulation is required to initiate the local release of nitric oxide, the inhibition of PDE5 has no effect in the absence of sexual stimulation.In vitro studies have shown that vardenafil is a selective inhibitor of PDE5.

Pseudoephedrine HCl (Sudafed)

The inhibitory effect of vardenafil is more selective on PDE5 than for other known phosphodiesterases (>15-fold relative to PDE6, >130-fold relative to PDE1, >300-fold relative to PDE11, and >1,000-fold relative to PDE2, 3, 4, 7, 8, 9, and 10).12.2 PharmacodynamicsThe pharmacodynamic studies described below were conducted using vardenafil film-coated tablets.Effects on Blood PressureIn a clinical pharmacology study of patients with erectile dysfunction, single doses of vardenafil 20 mg film-coated tablets caused a mean maximum decrease in supine blood pressure of 7 mmHg systolic and 8 mmHg diastolic (compared to placebo), accompanied by a mean maximum increase of heart rate of 4 beats per minute. Vardenafil may add to the blood pressure lowering effects of antihypertensive agents [see Drug Interactions (7)].Effects on Blood Pressure and Heart Rate when Vardenafil is Combined with NitratesA study was conducted in which the blood pressure and heart rate response to 0.4 mg nitroglycerin (NTG) sublingually was evaluated in 18 healthy subjects following pretreatment with vardenafil 20 mg film-coated tablets at various times before NTG administration. Additional blood pressure and heart rate changes were not detected when vardenafil 20 mg film-coated tablet was dosed 24 hours before NTG (see Figure 1).Figure 1: Placebo-subtracted point estimates (with 90% CI) of mean maximal blood pressure and heart rate effects of pre-dosing with vardenafil 20 mg at 24, 8, 4, and 1 hour before 0.4 mg NTG sublinguallyBecause the disease state of patients requiring nitrate therapy is anticipated to increase the likelihood of hypotension, the use of vardenafil by patients on nitrate therapy or on nitric oxide donors is contraindicated [see Contraindications (4.1)].Blood Pressure Effects in Patients on Stable Alpha-Blocker TreatmentThree clinical pharmacology studies were conducted in patients with benign prostatic hyperplasia (BPH) on stable-dose alpha-blocker treatment , consisting of alfuzosin, tamsulosin or terazosin.Study 1:This study was designed to evaluate the effect of 5 mg vardenafil film-coated tablets compared to placebo when administered to BPH patients on chronic alpha-blocker therapy in two separate cohorts: tamsulosin 0.4 mg daily (cohort 1, n=21) and terazosin 5 or 10 mg daily (cohort 2, n=21). The design was a randomized, double blind, cross-over study with four treatments: vardenafil 5 mg or placebo administered simultaneously with the alpha-blocker and vardenafil 5 mg or placebo administered 6 hours after the alpha-blocker. For blood pressure (BP) results, see Table 2. Additional blood pressure and heart rate changes were not detected when vardenafil 20 mg film-coated tablet was dosed 24 hours before NTG (see Figure 1).Figure 1: Placebo-subtracted point estimates (with 90% CI) of mean maximal blood pressure and heart rate effects of pre-dosing with vardenafil 20 mg at 24, 8, 4, and 1 hour before 0.4 mg NTG sublinguallyBecause the disease state of patients requiring nitrate therapy is anticipated to increase the likelihood of hypotension, the use of vardenafil by patients on nitrate therapy or on nitric oxide donors is contraindicated [see Contraindications (4.1)].Blood Pressure Effects in Patients on Stable Alpha-Blocker TreatmentThree clinical pharmacology studies were conducted in patients with benign prostatic hyperplasia (BPH) on stable-dose alpha-blocker treatment , consisting of alfuzosin, tamsulosin or terazosin.Study 1:This study was designed to evaluate the effect of 5 mg vardenafil film-coated tablets compared to placebo when administered to BPH patients on chronic alpha-blocker therapy in two separate cohorts: tamsulosin 0.4 mg daily (cohort 1, n=21) and terazosin 5 or 10 mg daily (cohort 2, n=21). The design was a randomized, double blind, cross-over study with four treatments: vardenafil 5 mg or placebo administered simultaneously with the alpha-blocker and vardenafil 5 mg or placebo administered 6 hours after the alpha-blocker. For blood pressure (BP) results, see Table 2. One patient, after simultaneous treatment with 5 mg vardenafil and 10 mg terazosin, exhibited symptomatic hypotension with standing blood pressure of 80/60 mmHg occurring one hour after administration generic levitra 24 h buy and subsequent mild dizziness and moderate lightheadedness lasting for 6 hours.

  • Liquid Levitra offers an alternative to pills for convenience.
  • It is primarily used to treat erectile dysfunction.
  • Suitable for those with difficulty swallowing tablets.

There were no cases of syncope.Table 2: Mean (95% CI) maximal change from baseline in systolic blood pressure (mmHg) following vardenafil 5 mg in BPH patients on stable alpha-blocker therapy (study 1)Blood pressure effects (standing SBP) in normotensive men on stable dose tamsulosin 0.4 mg following simultaneous administration of vardenafil 5 mg or placebo, or following administration of vardenafil 5 mg or placebo separated by 6 hours are shown in Figure 2.

Overdose/Missed Dose

Blood pressure effects (standing SBP) in normotensive men on stable dose terazosin (5 mg or 10 mg) following simultaneous administration of vardenafil 5 mg or placebo, or following administration of vardenafil 5 mg or placebo separated by 6 hours, are shown in Figure 3.Figure 2: Mean change from baseline in standing systolic blood pressure (mmHg) over 6 hour interval following simultaneous or 6 hr separation administration of vardenafil 5 mg or placebo with stable dose tamsulosin 0.4 mg in normotensive BPH patients (study 1)Figure 3: Mean change from baseline in standing systolic blood pressure (mmHg) over 6 hour interval following simultaneous or 6 hr separation administration of vardenafil 5 mg or placebo with stable dose terazosin (5 or 10 mg) in normotensive BPH patients (study 1)Study 2: This study was designed to evaluate the effect of 10 mg vardenafil (film-coated tablets) (stage 1) and 20 mg vardenafil (film-coated tablets) (stage 2) compared to placebo, when administered to a single cohort of BPH patients (n=23) on stable therapy with tamsulosin 0.4 mg or 0.8 mg daily for at least four weeks.

  • Common side effects include headache and flushing.
  • Serious side effects require immediate medical attention.
  • Hydration can reduce some minor side effects.

The design was a randomized, double blind, two-period, cross-over study. There were no cases of syncope.Table 3: Mean (95% CI) maximal change from baseline in systolic blood pressure (mmHg) following vardenafil 10 and 20 mg (film-coated tablets) in BPH patients on stable alpha-blocker therapy with tamsulosin 0.4 or 0.8 mg daily (study 2)Blood pressure effects (standing SBP) in normotensive men on stable dose of tamsulosin 0.4 mg following simultaneous administration of vardenafil 10 mg, vardenafil 20 mg or placebo are shown in Figure 4.Figure 4: Mean change from baseline in standing systolic blood pressure (mmHg) over 6 hour interval following simultaneous administration of vardenafil 10 mg film-coated tablet (stage 1), vardenafil 20 mg film-coated tablet (Stage 2), or placebo with stable dose tamsulosin price levitra 10mg 0.4 mg in normotensive BPH patients (study 2)Study 3: This study was designed to evaluate the effect of single doses of 5 mg vardenafil (stage 1) and 10 mg vardenafil (stage 2) compared to placebo, when administered to a single cohort of BPH patients (n=24) on stable therapy with alfuzosin 10 mg daily for at least four weeks. The design was a randomized, double blind, 3-period cross-over study. For BP results see Table 4.Table 4: Mean (95% C.I.) maximal change from baseline in systolic blood pressure (mmHg) following vardenafil 5 and 10 mg in BPH patients on stable alpha-blocker therapy with alfuzosin 10 mg daily (Study 3)One patient experienced decreases from baseline in standing systolic blood pressure >30 mm Hg after administration of vardenafil 5 mg film-coated tablets and vardenafil 10 mg film-coated tablets.

Therapeutic indication

Graphical abstract

Blood pressure effects (standing SBP) in normotensive men on a stable dose of alfuzosin 10 mg following administration of vardenafil 5 mg, vardenafil 10 mg, or placebo separated by 4 hours, are shown in Figure 5.Figure 5: Mean change from baseline in standing systolic blood pressure (mmHg) over 6 hour interval following 4 hr separation administration of vardenafil 5 mg (stage 1), vardenafil 10 mg (stage 2) or placebo with stable dose alfuzosin 10 mg in BPH patients (Study 3)Blood Pressure Effects in Normotensive Men After Forced Titration with Alpha-BlockersTwo randomized, double blind, placebo-controlled clinical pharmacology studies with healthy normotensive volunteers (age range, 45–74 years) were performed after forced titration of the alpha-blocker terazosin to 10 mg daily over 14 days (n=29), and after initiation of tamsulosin 0.4 mg daily for five days (n=24).

  • Proper disposal of expired or unused medication is vital.
  • Do not share medication with others.
  • Always consult your healthcare provider before starting.

Instances of outlier blood pressure values (defined as standing SBP <85 mmHg and/or a decrease from baseline of standing SBP >30 mmHg) were observed in 9/24 subjects receiving tamsulosin and 19/29 receiving terazosin.The incidence of subjects with standing SBP <85 mmHg given vardenafil and terazosin to achieve simultaneously the amount of time at the maximum concentration in serum (Tmax) led to early termination of that arm of the study.

Related services & treatments

One patient, after simultaneous treatment with 5 mg vardenafil and 10 mg terazosin, exhibited symptomatic hypotension with standing blood pressure of 80/60 mmHg occurring one hour after administration generic levitra 24 h buy and subsequent mild dizziness and moderate lightheadedness lasting for 6 hours. There were no cases of syncope.Table 2: Mean (95% CI) maximal change from baseline in systolic blood pressure (mmHg) following vardenafil 5 mg in BPH patients on stable alpha-blocker therapy (study 1)Blood pressure effects (standing SBP) in normotensive men on stable dose tamsulosin 0.4 mg following simultaneous administration of vardenafil 5 mg or placebo, or following administration of vardenafil 5 mg or placebo separated by 6 hours are shown in Figure 2. Blood pressure effects (standing SBP) in normotensive men on stable dose terazosin (5 mg or 10 mg) following simultaneous administration of vardenafil 5 mg or placebo, or following administration of vardenafil 5 mg or placebo separated by 6 hours, are shown in Figure 3.Figure 2: Mean change from baseline in standing systolic blood pressure (mmHg) over 6 hour interval following simultaneous or 6 hr separation administration of vardenafil 5 mg or placebo with stable dose tamsulosin 0.4 mg in normotensive BPH patients (study 1)Figure 3: Mean change from baseline in standing systolic blood pressure (mmHg) over 6 hour interval following simultaneous or 6 hr separation administration of vardenafil 5 mg or placebo with stable dose terazosin (5 or 10 mg) in normotensive BPH patients (study 1)Study 2: This study was designed to evaluate the effect of 10 mg vardenafil (film-coated tablets) (stage 1) and 20 mg vardenafil (film-coated tablets) (stage 2) compared to placebo, when administered to a single cohort of BPH patients (n=23) on stable therapy with tamsulosin 0.4 mg or 0.8 mg daily for at least four weeks. The design was a randomized, double blind, two-period, cross-over study. There were no cases of syncope.Table 3: Mean (95% CI) maximal change from baseline in systolic blood pressure (mmHg) following vardenafil 10 and 20 mg (film-coated tablets) in BPH patients on stable alpha-blocker therapy with tamsulosin 0.4 or 0.8 mg daily (study 2)Blood pressure effects (standing SBP) in normotensive men on stable dose of tamsulosin 0.4 mg following simultaneous administration of vardenafil 10 mg, vardenafil 20 mg or placebo are shown in Figure 4.Figure 4: Mean change from baseline in standing systolic blood pressure (mmHg) over 6 hour interval following simultaneous administration of vardenafil 10 mg film-coated tablet (stage 1), vardenafil 20 mg film-coated tablet (Stage 2), or placebo with stable dose tamsulosin price levitra 10mg 0.4 mg in normotensive BPH patients (study 2)Study 3: This study was designed to evaluate the effect of single doses of 5 mg vardenafil (stage 1) and 10 mg vardenafil (stage 2) compared to placebo, when administered to a single cohort of BPH patients (n=24) on stable therapy with alfuzosin 10 mg daily for at least four weeks.

Before taking vardenafil,

The design was a randomized, double blind, 3-period cross-over study. For BP results see Table 4.Table 4: Mean (95% C.I.) maximal change from baseline in systolic blood pressure (mmHg) following vardenafil 5 and 10 mg in BPH patients on stable alpha-blocker therapy with alfuzosin 10 mg daily (Study 3)One patient experienced decreases from baseline in standing systolic blood pressure >30 mm Hg after administration of vardenafil 5 mg film-coated tablets and vardenafil 10 mg film-coated tablets. Blood pressure effects (standing SBP) in normotensive men on a stable dose of alfuzosin 10 mg following administration of vardenafil 5 mg, vardenafil 10 mg, or placebo separated by 4 hours, are shown in Figure 5.Figure 5: Mean change from baseline in standing systolic blood pressure (mmHg) over 6 hour interval following 4 hr separation administration of vardenafil 5 mg (stage 1), vardenafil 10 mg (stage 2) or placebo with stable dose alfuzosin 10 mg in BPH patients (Study 3)Blood Pressure Effects in Normotensive Men After Forced Titration with Alpha-BlockersTwo randomized, double blind, placebo-controlled clinical pharmacology studies with healthy normotensive volunteers (age range, 45–74 years) were performed after forced titration of the alpha-blocker terazosin to 10 mg daily over 14 days (n=29), and after initiation of tamsulosin 0.4 mg daily for five days (n=24). Instances of outlier blood pressure values (defined as standing SBP <85 mmHg and/or a decrease from baseline of standing SBP >30 mmHg) were observed in 9/24 subjects receiving tamsulosin and 19/29 receiving terazosin.The incidence of subjects with standing SBP <85 mmHg given vardenafil and terazosin to achieve simultaneously the amount of time at the maximum concentration in serum (Tmax) led to early termination of that arm of the study. There were no cases of syncope.Table 5: Mean (95% CI) maximal change in baseline in systolic blood pressure (mmHg) following vardenafil 10 and 20 mg (film-coated tablets) in healthy volunteers on daily alpha-blocker therapy* Due to the sample size, confidence intervals may not be an accurate measure for these data.

Drug effects

There were no cases of syncope.Table 5: Mean (95% CI) maximal change in baseline in systolic blood pressure (mmHg) following vardenafil 10 and 20 mg (film-coated tablets) in healthy volunteers on daily alpha-blocker therapy* Due to the sample size, confidence intervals may not be an accurate measure for these data.

  • Vardenafil (Generic Equivalent of Levitra)
  • Cost-Effective Alternative to Levitra Tablets
  • Understanding Vardenafil 5mg: A Comprehensive Guide
  • Cenforce 150mg: How It Works for Erection Problems
  • Cost and Availability of Generic Sildenafil Fildena
  • Dostępność Levitry w krakowskich aptekach
  • Levitra (Vardenafil) – Informação para o doente

ZurückWeiter
123

In der Zahnarztpraxis Perren an der Bahnhofstrasse 4A in Brig-Glis finden sie die optimalen Voraussetzungen für eine nachhaltige Behandlung: Unser bestens qualifiziertes Team, modernste Ausrüstung sowie die Verwendung hochwertigster Materialien garantieren Ihnen Zahnmedizin gemäss dem neuesten Stand der Technik und auf höchstem Qualitätsniveau.

© Zahnarztpraxis Perren

  • Rechtliches
  • Privacy
  • Imprint
Nach oben scrollen

Diese Website verwendet Cookies.

EinverstandenInformationen

Cookie- und Datenschutzeinstellungen



Wie wir Cookies verwenden

Wir können Cookies anfordern, die auf Ihrem Gerät eingestellt werden. Wir verwenden Cookies, um uns mitzuteilen, wenn Sie unsere Websites besuchen, wie Sie mit uns interagieren, Ihre Nutzererfahrung verbessern und Ihre Beziehung zu unserer Website anpassen.

Klicken Sie auf die verschiedenen Kategorienüberschriften, um mehr zu erfahren. Sie können auch einige Ihrer Einstellungen ändern. Beachten Sie, dass das Blockieren einiger Arten von Cookies Auswirkungen auf Ihre Erfahrung auf unseren Websites und auf die Dienste haben kann, die wir anbieten können.

Notwendige Website Cookies

Diese Cookies sind unbedingt erforderlich, um Ihnen die auf unserer Webseite verfügbaren Dienste und Funktionen zur Verfügung zu stellen.

Da diese Cookies für die auf unserer Webseite verfügbaren Dienste und Funktionen unbedingt erforderlich sind, hat die Ablehnung Auswirkungen auf die Funktionsweise unserer Webseite. Sie können Cookies jederzeit blockieren oder löschen, indem Sie Ihre Browsereinstellungen ändern und das Blockieren aller Cookies auf dieser Webseite erzwingen. Sie werden jedoch immer aufgefordert, Cookies zu akzeptieren / abzulehnen, wenn Sie unsere Website erneut besuchen.

Wir respektieren es voll und ganz, wenn Sie Cookies ablehnen möchten. Um zu vermeiden, dass Sie immer wieder nach Cookies gefragt werden, erlauben Sie uns bitte, einen Cookie für Ihre Einstellungen zu speichern. Sie können sich jederzeit abmelden oder andere Cookies zulassen, um unsere Dienste vollumfänglich nutzen zu können. Wenn Sie Cookies ablehnen, werden alle gesetzten Cookies auf unserer Domain entfernt.

Wir stellen Ihnen eine Liste der von Ihrem Computer auf unserer Domain gespeicherten Cookies zur Verfügung. Aus Sicherheitsgründen können wie Ihnen keine Cookies anzeigen, die von anderen Domains gespeichert werden. Diese können Sie in den Sicherheitseinstellungen Ihres Browsers einsehen.

Andere externe Dienste

Wir nutzen auch verschiedene externe Dienste wie Google Webfonts, Google Maps und externe Videoanbieter. Da diese Anbieter möglicherweise personenbezogene Daten von Ihnen speichern, können Sie diese hier deaktivieren. Bitte beachten Sie, dass eine Deaktivierung dieser Cookies die Funktionalität und das Aussehen unserer Webseite erheblich beeinträchtigen kann. Die Änderungen werden nach einem Neuladen der Seite wirksam.

Google Webfont Einstellungen:

Google Maps Einstellungen:

Google reCaptcha Einstellungen:

Vimeo und YouTube Einstellungen:

Datenschutzrichtlinie

Sie können unsere Cookies und Datenschutzeinstellungen im Detail in unseren Datenschutzrichtlinie nachlesen.

Privacy
Einstellungen akzeptierenVerberge nur die Benachrichtigung